Allergy

 
Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose
March 28, 2025

Your daily dose of the clinical news you may have missed.

Underutilization of Guideline-Recommended Epinephrine in Anaphylaxis Management: New Study
March 26, 2025

A 5-year study conducted in Germany showed only 7% of adults and 8% of children with severe anaphylaxis received epinephrine.

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose
March 24, 2025

Your daily dose of the clinical news you may have missed.

Antibiotics, NSAIDs Reported Most Common Cause of Pediatric Anaphylaxis
March 18, 2025

Among pediatric patients aged 1 month to 18 years with emergent anaphylaxis, cephalosporins were the leading antibiotics and ibuprofen the top NSAID implicated in a new study.

Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose
March 17, 2025

Your daily dose of the clinical news you may have missed.

Dupilumab Cuts Food Allergy IgE Levels in Small Study: Daily Dose
March 14, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Neffy 1 mg Epinephrine Nasal Spray: Daily Dose
March 13, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar
March 10, 2025

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

FDA Approves Neffy 1 mg Epinephrine Nasal Spray, Only Needle-Free Treatment for Patients Weighing Less Than 30 kg
March 06, 2025

The FDA approval of neffy 1 mg follows the earlier approval of the 5 mg version in August 2024.

Depemokimab Shows Significant Improvements in Rhinosinusitis with Nasal Polyps: New Research
March 05, 2025

AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.